1-9 of 9
Diego Tosi
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 5729: Imiqualines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation

Kevin Bigot, Véronique Garambois, Nadia Vie, Marine Bruciamacchie, Pierre-Emmanuel Colombo, Diego Tosi, Cindy Patinote, Yann Maggipinto, Pierre-Antoine Bonnet, Céline Gongora, Carine Deleuze-Masquefa, Christel Larbouret
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5729.
https://doi.org/10.1158/1538-7445.AM2023-5729
Published: 04 April 2023
View article titled, Abstract 5729: Imiqualines for pancreatic cancer: first-in-class potent and synergistic inhibitors of microtubule polymerisation
Journal Articles

Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)

Martine Piccart, Audrey Hennequin, Manuel Ruiz Borrego, Santiago Escrivá-de-Romani, Anja Williams, Begoña Jiménez Rodríguez, Gianluca Del Conte, Sacha J. Howell, Michela Palleschi, Matteo Simonelli, Francois P. Duhoux, Diego Tosi, Bernard Doger de Speville Uribe, Yolanda Jerez Gilarranz, Pierfrancesco Tassone, Giuseppe Curigliano, Simon Waters, Philippe Aftimos, Hans Wildiers, Simona Scartoni, Bartomeu Piza Vallespir, Ram Charan Shankaraiah, Krzysztof Grzegorzewski, Nassir Habboubi
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): PD18-05.
https://doi.org/10.1158/1538-7445.SABCS22-PD18-05
Published: 01 March 2023
View article titled, Abstract PD18-05: MEN1611, a PI3K inhibitor, combined with trastuzumab ± fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)
Journal Articles

Abstract 2589: Effect of folfirinox with an ATR inhibitor on pancreatic tumor cells and its microenvironment

Marine Bruciamacchie, Nadia Vie, Véronique Garambois, Diego Tosi, Pierre-Emmanuel Colombo, Céline Gongora, Christel Larbouret
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 2589.
https://doi.org/10.1158/1538-7445.AM2022-2589
Published: 15 June 2022
View article titled, Abstract 2589: Effect of folfirinox with an ATR inhibitor on pancreatic tumor cells and its microenvironment
Journal Articles

Abstract CT131: Entrectinib in NTRK-fusion positive (NTRK-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)

Robert Doebele, Luis Paz-Ares, Anna F. Farago, Stephen V. Liu, Sant P. Chawla, Diego Tosi, Collin M. Blakely, John C. Krauss, Darren Sigal, Lyudmila Bazhenova, Tom John, Benjamin Besse, Jürgen Wolf, Takashi Seto, Edna Chow-Maneval, Chenglin Ye, Brian Simmons, George D. Demetri
Journal: Cancer Research
Cancer Res (2019) 79 (13_Supplement): CT131.
https://doi.org/10.1158/1538-7445.AM2019-CT131
Published: 01 July 2019
View article titled, Abstract CT131: Entrectinib in <em>NTRK</em>-fusion positive (<em>NTRK</em>-FP) non-small cell lung cancer (NSCLC): Integrated analysis of patients enrolled in three trials (STARTRK-2, STARTRK-1 and ALKA-372-001)
Journal Articles

Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (ATR) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer

Eve Combès, Augusto F. Andrade, Diego Tosi, Henri-Alexandre Michaud, Flavie Coquel, Veronique Garambois, Delphine Desigaud, Marta Jarlier, Arnaud Coquelle, Philippe Pasero, Nathalie Bonnefoy, Jerome Moreaux, Pierre Martineau, Maguy Del Rio, Roderick L. Beijersbergen, Nadia Vezzio-Vie, Celine Gongora
Journal: Cancer Research
Cancer Res (2019) 79 (11): 2933–2946.
https://doi.org/10.1158/0008-5472.CAN-18-2807
Published: 03 June 2019
View article titled, Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (<em>ATR</em>) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer
Open the PDF for Inhibition of Ataxia-Telangiectasia Mutated and RAD3-Related (<em>ATR</em>) Overcomes Oxaliplatin Resistance and Promotes Antitumor Immunity in Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract 1187: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells

Eve Combes, Augusto Faria-Andrade, Diego Tosi, Pierre Martineau, Maguy Del Rio, Roderick Beijersbergen, Nadia Vie, Céline Gongora
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 1187.
https://doi.org/10.1158/1538-7445.AM2017-1187
Published: 01 July 2017
View article titled, Abstract 1187: Synthetic lethality screening reveals ATR as responsible for oxaliplatin resistance in colorectal cancer cells
Journal Articles

Abstract 2378: A kinome analysis of the molecular pharmacodynamics of PT-112 in a human cancer cell line

Diego Tosi, Esther Perez-Gracia, Philippe Pourquier, Tyler D. Ames, Richard A. Wing, José Jimeno, Céline Gongora
Journal: Cancer Research
Cancer Res (2017) 77 (13_Supplement): 2378.
https://doi.org/10.1158/1538-7445.AM2017-2378
Published: 01 July 2017
View article titled, Abstract 2378: A kinome analysis of the molecular pharmacodynamics of PT-112 in a human cancer cell line
Journal Articles

Abstract 3681: Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines

Diego Tosi, Salima Atis, Caroline Mollevi, Pierre Martineau, Céline Gongora
Journal: Cancer Research
Cancer Res (2014) 74 (19_Supplement): 3681.
https://doi.org/10.1158/1538-7445.AM2014-3681
Published: 01 October 2014
View article titled, Abstract 3681: Synergism analysis of dose matrices for combinations of BKM120 (a PI3K inhibitor), MEK162 (a MEK1/2 inhibitor) and chemotherapy in colorectal cancer (CRC) cell lines
Journal Articles

Phase I study of anti fibronectin 131I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results

Diego Tosi, Angela Coliva, Carlo Chiesa, Cristiana Sessa, Antonella Perotti, Giuseppe Capri, Marco Maccauro, Ettore Seregni, Silvia Marsoni, Monica Miani, Hans Menssen, Dario Neri, Luciano Zardi, Emilio Bombardieri, Luca Gianni
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 947.
Published: 01 May 2007
View article titled, Phase I study of anti fibronectin <sup>131</sup>I-L19-small immunoprotein (SIP): Preliminary dosimetric, pharmacokinetics (PK) and therapeutic results